Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
--------------------------------------------------------------------
Source: CNBC
Published: 2026-08-05 20:45 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Financial Markets, Drugs
--------------------------------------------------------------------
Snippet:
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro surged again.
--------------------------------------------------------------------